Pharmafile Logo

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.

Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. 

Download and read the complimentary whitepaper at http://bit.ly/1Gmknh7  

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Video: Conducting mobile conference research

Our digital expert, Director John Branston explores how a mobile approach offers a better way of evaluating the impact of your conference presence

Free Thinking: From promise to practice: immuno-oncology in action

Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically...

Video: Syndicated patient record data

Track the global market in real time

Video: Patient level prescribing decisions

Quantitative Director Duncan Munro explores the benefits of using patient level prescribing decisions.There is no “one size fits all” approach to conducting demand assessments. The best studies utilise a methodology...

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

Pharmaceutical Market Research Conference 2016

Research Partnership exhibited and presented a paper at the Pharmaceutical Market Research Conference last week in Parsippany, NJ.Representing Research Partnership were US President Harriet Kozak and Director Phil Rosenberg.Harriet presented the paper...

Nicole Bender Moreira promoted to Associate Director, Singapore office

Research Partnership is delighted to announce the promotion of Nicole Bender Moreira to Associate Director in recognition of the contribution she has made to the growing success of our Singapore...

New appointments announced across Research Partnership’s global offices

We are delighted to welcome Marianne Jaeger as Associate Director to our London headquarters

What to Consider When Conducting Patient Research in Saudi Arabia

The need to understand the patient as a key stakeholder is now recognized by pharma across the globe.

Research Partnership hires Graphic Designer to create storytelling deliverables

Research Partnership has extended its healthcare research and consulting offering to include storytelling deliverables with the hire of multi-media graphic designer Amanda Brent at the company’s London headquarters. Working with...